At the upcoming, annual San Antonio Breast Cancer Symposium, NanoString Technologies, Seattle, Wash, will present three posters on its in vitro diagnostic breast cancer assay (based on the PAM50 gene expression signature).
The PAM50-based breast cancer assay provides a subtype classification based on the fundamental biology of an individual’s breast tumor. Of these posters, one will reveal results from NanoString’s second clinical validation study for prognosis in postmenopausal women with hormone-receptor positive, early-stage breast cancer treated with endocrine therapy alone.
Information about the posters is shown below:
Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer
Session: Poster Session 2 (Prognostic Factors and Biomarkers – Clinical Testing and Validation)
Abstract: P2-10-02
Lead Author: Michael Gnant, MD
Date/Time: December 6, from 7 am to 9 am Central Time
Location: Exhibit Halls A-B
PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy
Session: Poster Session 2 (Prognostic Factors and Biomarkers – Clinical Testing and Validation)
Abstract: P2-10-01
Lead Author: Minetta C Liu, MD
Date/Time: December 6, from 7 am to 9 am Central Time
Location: Exhibit Halls A-B
Association between PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
Session: Poster Session 3 (Response Predictions – Biomarkers and Other Factors)
Abstract: P3-06-03
Lead Author: Charlotte LT Jorgensen, MSc
Date/Time: December 6, from 5 pm to 7 pm Central Time
Location: Exhibit Halls A-B
[Source: NanoString Technologies]
